Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of relapsing multiple sclerosis in Hungary - consensus recommendation from the Hungarian neuroimmunology society.
Rajda C, Rózsa C, Mike A, Lovas G, Mezei Z, Jakab G, Ács P, Rum G, Simó M, Jobbágy Z, Bíró Z, Trauninger A, Imre P, Mátyás K, Deme I, Illés Z, Csepany T. Rajda C, et al. Among authors: biro z. Orphanet J Rare Dis. 2023 Jul 7;18(1):183. doi: 10.1186/s13023-023-02789-0. Orphanet J Rare Dis. 2023. PMID: 37420270 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis.
Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, Kölsche T, Korsen M, Grothe M, Groppa S, Luessi F, Engel S, Nelles G, Bonmann E, Roick H, Friedrich A, Knorn P, Landefeld H, Biro Z, Ernst M, Bayas A, Menacher M, Akgün K, Kleinschnitz C, Ruck T, Ziemssen T, Pul R, Meuth SG. Regner-Nelke L, et al. Among authors: biro z. Neurol Res Pract. 2022 Nov 7;4(1):55. doi: 10.1186/s42466-022-00219-3. Neurol Res Pract. 2022. PMID: 36336685 Free PMC article.
Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group. Oddone F, et al. Adv Ther. 2022 Aug;39(8):3522-3523. doi: 10.1007/s12325-022-02210-5. Adv Ther. 2022. PMID: 35731341 Free PMC article. No abstract available.
Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G; VISIONARY Study Group. Oddone F, et al. Adv Ther. 2022 Aug;39(8):3501-3521. doi: 10.1007/s12325-022-02166-6. Epub 2022 May 7. Adv Ther. 2022. PMID: 35524840 Free PMC article.
83 results